Imunon Stock Soars 12.14% on Earnings Hype, Short Interest Surge

On June 6, 2025, Imunon's stock surged by 12.14% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Imunon's recent performance can be attributed to several key factors. The company's upcoming earnings report for Q2 2025, scheduled for August 13, 2025, is highly anticipated. Additionally, the stock's short interest has seen a notable increase of 12.60%, indicating heightened speculative activity.

Imunon is also set to present translational data supporting remarkable Phase 2 ovarian cancer survival results at the ESMO Gynaecological Cancers Congress 2025. This presentation is expected to further bolster investor confidence in the company's innovative research and development efforts.

Looking ahead, the stock is forecasted to rise by 17.50% over the next three months, with a 90% probability of holding a price between $0.525 and higher. This optimistic outlook is driven by the company's strong pipeline and potential breakthroughs in cancer treatment.